Serum procollagen III peptide levels in subjects with sarcoidosis

A 5- year follow-up study

W. R. Pohl, Austin Bassett Thompson, H. Kohn, S. Losch, H. Umek, E. Legenstein, F. Kummer, Stephen Israel Rennard, H. Klech

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In a prospective study, Type III procollagen N-terminal peptide was measured in the sera of 38 subjects with biopsy-proven pulmonary sarcoidosis at 6-month intervals over a period of 5 yr. The subjects were divided into four groups according to their radiologic presentation and clinical course: Group A (n = 10) subjects with sarcoidosis Type I without radiologic progression over 5 yr; Group B (n = 5) subjects with sarcoidosis Type I with radiologic progression to Stage II or III; Group C (n = 9) subjects with sarcoidosis Types II and III without progression over 5 yr; and Group D (n = 14) subjects with sarcoidosis Types II and III with radiologic progression. Lung function tests (FVC, FEV1, and DL(CO)), chest roentgenograms, and measurements of serum angiotensin converting enzyme (S-ACE) were performed concurrently with the S-PCP-III levels. Significantly higher levels of S-PCP- III were found in group B (Type I, progressive) (18.2 ± 1.09 ng/ml) and in group D (Type II/III, progressive) (13.9 ± 1.2 ng/ml) compared with those of Group A (Type I, stable) (9.1 ± 1.09 ng/ml) and Group C (Type II/III, stable) (7.6 ± 1.1 ng/ml) or normal volunteers (9.4 ± 4 ng/ml) (p < 0.001 for all comparisons). Changes in S-PCP-III levels tended to parallel the clinical course, and steroid treatment resulted in a significant decrease in S-PCP-III concentrations (p < 0.001). In contrast, serum angiotensin converting enzyme (S-ACE) levels did not correlate with either the clinical course or radiologic changes. In conclusion, subjects with active sarcoidosis demonstrated significantly higher S-PCP-III levels than subjects with inactive disease. Additionally, increased S-PCP-III concentrations could be observed in subjects who deteriorated clinically and radiologically within the period of observation.

Original languageEnglish (US)
Pages (from-to)412-417
Number of pages6
JournalAmerican Review of Respiratory Disease
Volume145
Issue number2 II SUPPL.
StatePublished - Jan 1 1992

Fingerprint

Procollagen
Sarcoidosis
Peptides
Serum
Peptidyl-Dipeptidase A
Pulmonary Sarcoidosis
Respiratory Function Tests
Carbon Monoxide
procollagen Type III-N-terminal peptide
Healthy Volunteers
Thorax
Steroids
Observation
Prospective Studies
Biopsy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pohl, W. R., Thompson, A. B., Kohn, H., Losch, S., Umek, H., Legenstein, E., ... Klech, H. (1992). Serum procollagen III peptide levels in subjects with sarcoidosis: A 5- year follow-up study. American Review of Respiratory Disease, 145(2 II SUPPL.), 412-417.

Serum procollagen III peptide levels in subjects with sarcoidosis : A 5- year follow-up study. / Pohl, W. R.; Thompson, Austin Bassett; Kohn, H.; Losch, S.; Umek, H.; Legenstein, E.; Kummer, F.; Rennard, Stephen Israel; Klech, H.

In: American Review of Respiratory Disease, Vol. 145, No. 2 II SUPPL., 01.01.1992, p. 412-417.

Research output: Contribution to journalArticle

Pohl, WR, Thompson, AB, Kohn, H, Losch, S, Umek, H, Legenstein, E, Kummer, F, Rennard, SI & Klech, H 1992, 'Serum procollagen III peptide levels in subjects with sarcoidosis: A 5- year follow-up study', American Review of Respiratory Disease, vol. 145, no. 2 II SUPPL., pp. 412-417.
Pohl, W. R. ; Thompson, Austin Bassett ; Kohn, H. ; Losch, S. ; Umek, H. ; Legenstein, E. ; Kummer, F. ; Rennard, Stephen Israel ; Klech, H. / Serum procollagen III peptide levels in subjects with sarcoidosis : A 5- year follow-up study. In: American Review of Respiratory Disease. 1992 ; Vol. 145, No. 2 II SUPPL. pp. 412-417.
@article{3e8bcc6a76cd45c9898e61cb60ef0838,
title = "Serum procollagen III peptide levels in subjects with sarcoidosis: A 5- year follow-up study",
abstract = "In a prospective study, Type III procollagen N-terminal peptide was measured in the sera of 38 subjects with biopsy-proven pulmonary sarcoidosis at 6-month intervals over a period of 5 yr. The subjects were divided into four groups according to their radiologic presentation and clinical course: Group A (n = 10) subjects with sarcoidosis Type I without radiologic progression over 5 yr; Group B (n = 5) subjects with sarcoidosis Type I with radiologic progression to Stage II or III; Group C (n = 9) subjects with sarcoidosis Types II and III without progression over 5 yr; and Group D (n = 14) subjects with sarcoidosis Types II and III with radiologic progression. Lung function tests (FVC, FEV1, and DL(CO)), chest roentgenograms, and measurements of serum angiotensin converting enzyme (S-ACE) were performed concurrently with the S-PCP-III levels. Significantly higher levels of S-PCP- III were found in group B (Type I, progressive) (18.2 ± 1.09 ng/ml) and in group D (Type II/III, progressive) (13.9 ± 1.2 ng/ml) compared with those of Group A (Type I, stable) (9.1 ± 1.09 ng/ml) and Group C (Type II/III, stable) (7.6 ± 1.1 ng/ml) or normal volunteers (9.4 ± 4 ng/ml) (p < 0.001 for all comparisons). Changes in S-PCP-III levels tended to parallel the clinical course, and steroid treatment resulted in a significant decrease in S-PCP-III concentrations (p < 0.001). In contrast, serum angiotensin converting enzyme (S-ACE) levels did not correlate with either the clinical course or radiologic changes. In conclusion, subjects with active sarcoidosis demonstrated significantly higher S-PCP-III levels than subjects with inactive disease. Additionally, increased S-PCP-III concentrations could be observed in subjects who deteriorated clinically and radiologically within the period of observation.",
author = "Pohl, {W. R.} and Thompson, {Austin Bassett} and H. Kohn and S. Losch and H. Umek and E. Legenstein and F. Kummer and Rennard, {Stephen Israel} and H. Klech",
year = "1992",
month = "1",
day = "1",
language = "English (US)",
volume = "145",
pages = "412--417",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2 II SUPPL.",

}

TY - JOUR

T1 - Serum procollagen III peptide levels in subjects with sarcoidosis

T2 - A 5- year follow-up study

AU - Pohl, W. R.

AU - Thompson, Austin Bassett

AU - Kohn, H.

AU - Losch, S.

AU - Umek, H.

AU - Legenstein, E.

AU - Kummer, F.

AU - Rennard, Stephen Israel

AU - Klech, H.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - In a prospective study, Type III procollagen N-terminal peptide was measured in the sera of 38 subjects with biopsy-proven pulmonary sarcoidosis at 6-month intervals over a period of 5 yr. The subjects were divided into four groups according to their radiologic presentation and clinical course: Group A (n = 10) subjects with sarcoidosis Type I without radiologic progression over 5 yr; Group B (n = 5) subjects with sarcoidosis Type I with radiologic progression to Stage II or III; Group C (n = 9) subjects with sarcoidosis Types II and III without progression over 5 yr; and Group D (n = 14) subjects with sarcoidosis Types II and III with radiologic progression. Lung function tests (FVC, FEV1, and DL(CO)), chest roentgenograms, and measurements of serum angiotensin converting enzyme (S-ACE) were performed concurrently with the S-PCP-III levels. Significantly higher levels of S-PCP- III were found in group B (Type I, progressive) (18.2 ± 1.09 ng/ml) and in group D (Type II/III, progressive) (13.9 ± 1.2 ng/ml) compared with those of Group A (Type I, stable) (9.1 ± 1.09 ng/ml) and Group C (Type II/III, stable) (7.6 ± 1.1 ng/ml) or normal volunteers (9.4 ± 4 ng/ml) (p < 0.001 for all comparisons). Changes in S-PCP-III levels tended to parallel the clinical course, and steroid treatment resulted in a significant decrease in S-PCP-III concentrations (p < 0.001). In contrast, serum angiotensin converting enzyme (S-ACE) levels did not correlate with either the clinical course or radiologic changes. In conclusion, subjects with active sarcoidosis demonstrated significantly higher S-PCP-III levels than subjects with inactive disease. Additionally, increased S-PCP-III concentrations could be observed in subjects who deteriorated clinically and radiologically within the period of observation.

AB - In a prospective study, Type III procollagen N-terminal peptide was measured in the sera of 38 subjects with biopsy-proven pulmonary sarcoidosis at 6-month intervals over a period of 5 yr. The subjects were divided into four groups according to their radiologic presentation and clinical course: Group A (n = 10) subjects with sarcoidosis Type I without radiologic progression over 5 yr; Group B (n = 5) subjects with sarcoidosis Type I with radiologic progression to Stage II or III; Group C (n = 9) subjects with sarcoidosis Types II and III without progression over 5 yr; and Group D (n = 14) subjects with sarcoidosis Types II and III with radiologic progression. Lung function tests (FVC, FEV1, and DL(CO)), chest roentgenograms, and measurements of serum angiotensin converting enzyme (S-ACE) were performed concurrently with the S-PCP-III levels. Significantly higher levels of S-PCP- III were found in group B (Type I, progressive) (18.2 ± 1.09 ng/ml) and in group D (Type II/III, progressive) (13.9 ± 1.2 ng/ml) compared with those of Group A (Type I, stable) (9.1 ± 1.09 ng/ml) and Group C (Type II/III, stable) (7.6 ± 1.1 ng/ml) or normal volunteers (9.4 ± 4 ng/ml) (p < 0.001 for all comparisons). Changes in S-PCP-III levels tended to parallel the clinical course, and steroid treatment resulted in a significant decrease in S-PCP-III concentrations (p < 0.001). In contrast, serum angiotensin converting enzyme (S-ACE) levels did not correlate with either the clinical course or radiologic changes. In conclusion, subjects with active sarcoidosis demonstrated significantly higher S-PCP-III levels than subjects with inactive disease. Additionally, increased S-PCP-III concentrations could be observed in subjects who deteriorated clinically and radiologically within the period of observation.

UR - http://www.scopus.com/inward/record.url?scp=0026558633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026558633&partnerID=8YFLogxK

M3 - Article

VL - 145

SP - 412

EP - 417

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2 II SUPPL.

ER -